mRNA cancer vaccines: Advances, trends and challenges
Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-07-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522001198 |
| _version_ | 1818532502436839424 |
|---|---|
| author | Qing He Hua Gao Dejiang Tan Heng Zhang Jun-zhi Wang |
| author_facet | Qing He Hua Gao Dejiang Tan Heng Zhang Jun-zhi Wang |
| author_sort | Qing He |
| collection | DOAJ |
| description | Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are relatively easy to control and can be rapidly mass produced. In 2021, the U.S. Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer and BioNTech, which has generated enthusiasm for mRNA vaccine research and development. Based on the above characteristics and the development of mRNA vaccines, mRNA cancer vaccines have become a research hotspot and have undergone rapid development, especially in the last five years. This review analyzes the advances in mRNA cancer vaccines from various perspectives, including the selection and expression of antigens/targets, the application of vectors and adjuvants, different administration routes, and preclinical evaluation, to reflect the trends and challenges associated with these vaccines. |
| first_indexed | 2024-12-11T17:46:22Z |
| format | Article |
| id | doaj.art-57bb82ecb6384080b6eca054b6549c83 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-12-11T17:46:22Z |
| publishDate | 2022-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-57bb82ecb6384080b6eca054b6549c832022-12-22T00:56:21ZengElsevierActa Pharmaceutica Sinica B2211-38352022-07-0112729692989mRNA cancer vaccines: Advances, trends and challengesQing He0Hua Gao1Dejiang Tan2Heng Zhang3Jun-zhi Wang4National Institutes for Food and Drug Control, State Key Laboratory for Evaluation and Standardization of Innovative Vaccines and Biotechnology Products, Beijing 102629, ChinaNational Institutes for Food and Drug Control, State Key Laboratory for Evaluation and Standardization of Innovative Vaccines and Biotechnology Products, Beijing 102629, ChinaNational Institutes for Food and Drug Control, State Key Laboratory for Evaluation and Standardization of Innovative Vaccines and Biotechnology Products, Beijing 102629, ChinaNational Institutes for Food and Drug Control, State Key Laboratory for Evaluation and Standardization of Innovative Vaccines and Biotechnology Products, Beijing 102629, ChinaCorresponding author.; National Institutes for Food and Drug Control, State Key Laboratory for Evaluation and Standardization of Innovative Vaccines and Biotechnology Products, Beijing 102629, ChinaPatients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are relatively easy to control and can be rapidly mass produced. In 2021, the U.S. Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer and BioNTech, which has generated enthusiasm for mRNA vaccine research and development. Based on the above characteristics and the development of mRNA vaccines, mRNA cancer vaccines have become a research hotspot and have undergone rapid development, especially in the last five years. This review analyzes the advances in mRNA cancer vaccines from various perspectives, including the selection and expression of antigens/targets, the application of vectors and adjuvants, different administration routes, and preclinical evaluation, to reflect the trends and challenges associated with these vaccines.http://www.sciencedirect.com/science/article/pii/S2211383522001198mRNACancer vaccineTumor-associated antigensNeoantigensmRNA delivery vectorsAdjuvants |
| spellingShingle | Qing He Hua Gao Dejiang Tan Heng Zhang Jun-zhi Wang mRNA cancer vaccines: Advances, trends and challenges Acta Pharmaceutica Sinica B mRNA Cancer vaccine Tumor-associated antigens Neoantigens mRNA delivery vectors Adjuvants |
| title | mRNA cancer vaccines: Advances, trends and challenges |
| title_full | mRNA cancer vaccines: Advances, trends and challenges |
| title_fullStr | mRNA cancer vaccines: Advances, trends and challenges |
| title_full_unstemmed | mRNA cancer vaccines: Advances, trends and challenges |
| title_short | mRNA cancer vaccines: Advances, trends and challenges |
| title_sort | mrna cancer vaccines advances trends and challenges |
| topic | mRNA Cancer vaccine Tumor-associated antigens Neoantigens mRNA delivery vectors Adjuvants |
| url | http://www.sciencedirect.com/science/article/pii/S2211383522001198 |
| work_keys_str_mv | AT qinghe mrnacancervaccinesadvancestrendsandchallenges AT huagao mrnacancervaccinesadvancestrendsandchallenges AT dejiangtan mrnacancervaccinesadvancestrendsandchallenges AT hengzhang mrnacancervaccinesadvancestrendsandchallenges AT junzhiwang mrnacancervaccinesadvancestrendsandchallenges |